Provided by Tiger Fintech (Singapore) Pte. Ltd.

Esperion Therapeutics

1.17
-0.0300-2.50%
Post-market: 1.170.00000.00%19:55 EDT
Volume:2.15M
Turnover:2.55M
Market Cap:231.89M
PE:-1.45
High:1.22
Open:1.18
Low:1.16
Close:1.20
Loading ...

Esperion Therapeutics Inc expected to post a loss of 15 cents a share - Earnings Preview

Reuters
·
28 Feb

Xeris Biopharma (XERS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Zacks
·
26 Feb

Will Esperion Therapeutics (ESPR) Report Negative Earnings Next Week? What You Should Know

Zacks
·
25 Feb

Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4

GlobeNewswire
·
18 Feb

BRIEF-Esperion Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
14 Feb

Esperion Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
14 Feb

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
14 Feb

Esperion Therapeutics Price Target Maintained With a $16.00/Share by HC Wainwright & Co.

Dow Jones
·
11 Feb

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Incyte (INCY), Enanta Pharmaceuticals (ENTA) and Esperion (ESPR)

TIPRANKS
·
11 Feb

Esperion (ESPR) Receives a Sell from Bank of America Securities

TIPRANKS
·
04 Feb

Esperion Therapeutics Price Target Maintained With a $16.00/Share by HC Wainwright & Co.

Dow Jones
·
23 Jan

Bank of America Securities Reaffirms Their Sell Rating on Esperion (ESPR)

TIPRANKS
·
16 Jan

Esperion to Host Virtual Key Opinion Leader Event on Wednesday, January 22, 2025, at 11:30 a.m. ET.

GlobeNewswire
·
09 Jan

Esperion to Participate in Upcoming 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire
·
02 Jan

Esperion Therapeutics Completes Financing Deals to Partially Repay Convertible Debt

MT Newswires Live
·
18 Dec 2024

Esperion Strengthens Balance Sheet With Closing of Significant Refinancing Transactions

THOMSON REUTERS
·
18 Dec 2024

Esperion Therapeutics Price Target Announced at $4.00/Share by Goldman Sachs

Dow Jones
·
18 Dec 2024

Paul Choi Assigns Hold Rating to Esperion Due to Market Uncertainty and Pipeline Challenges

TIPRANKS
·
18 Dec 2024

Esperion Therapeutics Initiated at Overweight by Cantor Fitzgerald

Dow Jones
·
17 Dec 2024

Cantor Fitzgerald Initiates Esperion Therapeutics at Overweight With $8 Price Target

MT Newswires Live
·
17 Dec 2024